Tumor-specific neoantigen-MHC complex

The tumor-specific neoantigen-MHC complex is a molecular structure on the surface of tumor cells formed by the binding of a tumor-derived mutated peptide (neoantigen) to a major histocompatibility complex (MHC) protein. These complexes are crucial for immune surveillance, as they allow cytotoxic T cells to specifically recognize and eliminate tumor cells based on mutations unique to the tumor. This specificity makes the complex an attractive target for cancer immunotherapy, including personalized T cell therapies, neoantigen-based vaccines, and antibody-based approaches. The success of these modalities depends on the immunogenicity of the presented neoantigen, its ability to bind MHC and be recognized by the TCR, and its absence from normal cells to avoid autoimmunity. Therapeutic manipulation aims to enhance the presentation, recognition, and immune activation against these complexes for targeted tumor destruction[5][2][3][4][1].

Other names

Neoantigen-MHC complexNeoantigen–MHC–peptide complexTumor neoantigen-MHC complexTumor-specific pMHCNeoepitope–MHC complex

Direct recognition and binding by engineered TCRs or antibodies to the neoantigen-MHC complex, leading to T cell activation and tumor cell killing[4][3] Vaccination or gene therapy to promote presentation of neoantigen-MHC complexes and enhance immune targeting[2][5] Bispecific antibody-mediated engagement of T cells with tumor cells presenting the neoantigen-MHC complex[3]